Cytodyn Inc (CYDY)

[Saltz]

IMO, yes Adjuct is likely in the bag but that will result in a BO below1 Billion, in the $3 per share range. It would be nice insurance even at $3 a share if P3 Mono results are disappointing. I mean $3 is better than zero and that is the risk factor in an OTC Biotech - absolutely zero.

Going forward I have to believe Nader (not Nadar) has resolved the patient screening issues they experienced with the P2b trial. To risk inaccurate screening with the 300 patient P3 300 Mono would be a fatal mistake. If Nader has this resolved things are going to get very interesting as the data comes in. We will leave .70 and the OTC in our rear view mirrors and this chapter will be a forgotten nightmare.

Between all of the cheap shares that are acquired through the private raises that are in endless supply, OTC manipulation and trading restraints, and some unanswered questions regarding the data it's simple- we are where we are for a reason. We have not been de-risked to a level that gets BP to turn their chair around -- ever watched "The Voice". All we need is one chair to turn to validate. It's a big chair to get turned but when it turns others will follow.

Where's Wallstreet and his "little birdies"? Time for some chirping come January.